CHRIS J. D. ZARAFONETIS, M.D., F.A.C.P.
Scleroderma, or diffuse systemic sclerosis, is a challenging disease. Its etiology is not known and its pathogenesis is poorly understood. The clinical and histopathologic features of scleroderma, however, have been repeatedly described1, 2, 3 and need be mentioned only briefly here. Characteristically there is cutaneous involvement, usually ushered in by an acute edematous phase, followed by induration and then atrophy. Raynaud's phenomenon may precede, accompany or, rarely, follow the onset of objective skin change. Pain and stiffness of joints, and myalgias are not uncommon. Although the changes in the skin may dominate the clinical picture, it is now well known
ZARAFONETIS CJD. TREATMENT OF SCLERODERMA(TREATMENT OF SCLERODERMA*). Ann Intern Med. 1959;50:343–365. doi: 10.7326/0003-4819-50-2-343
Download citation file:
Published: Ann Intern Med. 1959;50(2):343-365.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use